Navigation Links
Pharmacyclics Reports Fiscal 2012 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 53rd American Society of Hematology Annual Meeting
Date:11/7/2011

t candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations and beliefs regarding our future results or performance. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. Our actual results could differ materially from those projected in the forward-looking statements. Additionally, you should not consider past results to be an indication of our future performance. For a discussion of the risk factors and other factors that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our annual report on Form 10-K and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
2. Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
3. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
4. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
5. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
6. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
7. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
8. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
9. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
10. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
11. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... The Temple Health & Bioscience District (THBD) today ... at 1802 South First St. in the Temple Medical and ... City of Temple to receive funding for ... Texas Veterans Health Care System, the new facility will enable ... biotechnology and life science companies. ...
(Date:3/27/2015)... March 27, 2015 XRpro Sciences, Inc., ... discovery and development services which features high throughput ... industry, announced financial results for the year ended ...  Tyson, Chairman of XRpro Sciences commented, "We have ... from development stage to commercial stage in large ...
(Date:3/27/2015)... 2015 As of February, InControl Medical, ... for women. "Shipping thousands of our ... is the hundreds of letters, emails and phone ... been positively impacted by our technology," said ... InControl recently released Apex, an over-the-counter solution for ...
Breaking Medicine Technology:Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2
... Life Sciences Holdings, Inc. (OTC Bulletin ... in the discovery, development and commercialization of novel drugs ... diseases, announced today that Dawson James Securities Inc., has ... report highlights Restanza™ (cethromycin) as a promising late-stage antibacterial ...
... 2010 HealthLeaders-InterStudy, a leading provider of managed ... a shift toward coordinated patient care in Portland, ... to the Portland, Maine Market Overview, ... coordinated care models such as patient-centered medical homes ...
Cached Medicine Technology:Dawson James Initiates Research Coverage of Advanced Life Sciences 2Dawson James Initiates Research Coverage of Advanced Life Sciences 3Consolidated Portland, Maine Healthcare Market Will Hamper Pharmaceutical Reps' Access to Physicians 2
(Date:3/28/2015)... March 28, 2015 ARDX will sponsor the ... 12pm -3pm at the Chesapeake Conference Center in Chesapeake, Virginia. ... an empowering event for women in the Hampton Roads region. ... Stories of Women’s Lives. Women grow stronger through sharing ... other. This year the WWC™ theme is T-talk where ...
(Date:3/28/2015)... Paso Robles, CA (PRWEB) March 28, 2015 ... damage restoration specialists , this week released a report ... worsen the symptoms of asthma sufferers, and according to ... healthy children. , According to the Environmental Protection ... can develop asthmatic reactions. Breathing in mold may trigger ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 The ... from dating experts Samantha Sanderson and Jason Rogers has ... buzz of media attention. The commotion surrounding the course's ... prompting him to publish an in-depth review of the ... when the men in their lives suddenly start pulling ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 In her mid-forties ... prevented her from working, Monica K. arrived at JET ... mending department quiet, defensive and scared. The owners and staff ... Support Services (EPSS) to offer jobs to challenged residents ... patience and a willingness to begin with the end in ...
(Date:3/27/2015)... The federal court overseeing thousands of ... medication increases the risk that a patient will develop ... Dismiss four individual cases that had been filed in ... in the U.S. District Court, District of South Carolina, ... were warranted because the plaintiffs in those claims had ...
Breaking Medicine News(10 mins):Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3
... of Matthew L. Myers, President, Campaign for ... following is a,statement of Matthew L. Myers, President, ... for Latin America and the world, both the,Mexico ... Tuesday,took significant action to reduce tobacco use and ...
... 2008) MIT graduate student and synthetic biologist ... pose threats to human health. His current mission: ... M.D. candidate and Ph.D. in the Harvard-MIT Division ... $30,000 Lemelson-MIT Student Prize for inventing processes that ...
... Bradley Kropp of Faculty of 1000 Medicine, researchers find ... of bowel function after gastrointestinal surgery a problem ... , Authors of the paper published in Urology evaluated ... them 5 pieces of chewing gum per day after ...
... TRAVERSE CITY, Mich., Feb. 27 Versus,Technology, Inc. ... its first fiscal quarter ended January 31, 2008, ... same quarter of the prior,year. Versus, quarterly revenues ... of major customer projects. Accordingly, the revenues,reported in ...
... by Swiss-Based In-House Counsel, To Proceed against Altria Group, Inc. and ... ... Inc., NEW YORK, Feb. 27 Broach & Stulberg, LLP announced,today ... for the Southern District of New York has denied motions to,dismiss age ...
... Feb. 27 To coincide with the annual,HIMSS ... announced a new release and new pricing of,its ... users,of EMR (Electronic Medical Records) software to scan ... package which is hosted on,Citrix(R) or Windows Terminal ...
Cached Medicine News:Health News:Mexico City's New Smoke-Free Law Sets Example for Latin America and World 2Health News:Mexico City's New Smoke-Free Law Sets Example for Latin America and World 3Health News:Bacteria beware: MIT student invents knock-out punch for antibiotic resistance 2Health News:Bacteria beware: MIT student invents knock-out punch for antibiotic resistance 3Health News:Bacteria beware: MIT student invents knock-out punch for antibiotic resistance 4Health News:Versus Technology Announces First Quarter Results 2Health News:Versus Technology Announces First Quarter Results 3Health News:Versus Technology Announces First Quarter Results 4Health News:Versus Technology Announces First Quarter Results 5Health News:Versus Technology Announces First Quarter Results 6Health News:Court Denies Tobacco Giants' Motions to Dismiss Claims Alleging Explicit Age Discrimination and Retaliation 2Health News:Court Denies Tobacco Giants' Motions to Dismiss Claims Alleging Explicit Age Discrimination and Retaliation 3Health News:RemoteScan - Scanner Connectivity Software for EMR (Electronic Medical Record) Systems 2
... has created this extremely versatile and efficient ... liquid handling. With EDOS, high sample throughput ... with ease. ,The smallest volume that ... corresponding Combitip. The easy-to-follow user menus presented ...
... Dilutor-Dispenser is designed to transfer ... the clinical, biological, and chemical ... and performance as Gilsons other ... is ideal for routine laboratory ...
... synQUAD technology is a patented non-contact dispensing ... with a microsolenoid valve and stage stepper ... of liquid onto various slides, plates, or ... well, coefficient of variation (CVs) are less ...
16 channel Parallel dispenser using Positive Air Displacement Technology...
Medicine Products: